Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers

Abhyankar, Dhiraj; Shedage, Ashish; Gole, Milind; Raut, Preeti

doi:10.1177/1533317517712890

Cited by 1 publication

(1 citation statement)

References 13 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary treatment for AD involves pharmacological therapy, including cholinesterase inhibitors, NMDA receptor antagonists, Aβ inhibitors, and intestinal flora modulators [12]. Although medication may alleviate AD-induced cognitive and memory impairments to some extent, it cannot stop the progression or cure this neurodegenerative disease.…”

Section: Introductionmentioning

confidence: 99%

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer’s disease: A meta-analysis

Zang,

Liu,

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Although Alzheimer’s disease (AD) mainly affects cognitive function, it is often accompanied by sleep disorders and psychobehavioral symptoms. These symptoms, including depression, agitation, and psychotic symptoms, are prominent hospitalization causes among patients with AD. Currently, relatively more research exists on light therapy for sleep disorders, while those on psychobehavioral symptoms are gradually increasing. However, no consensus exists on these results because of the vulnerability of light therapy to multiple factors, including light intensity and duration. Thus, further research investigating this aspect is warranted. Objective To evaluate the efficacy of light therapy in improving sleep disorders and psychobehavioural symptoms in patients with AD. Methods In this meta-analysis, relevant literature was searched in Embase, the Clinical Trials Registry, Web of Science, PubMed, and the Cochrane Library up to December 2022. Furthermore, a fixed-effects model was used for data analysis. Results Fifteen randomized controlled trials involving 598 patients with AD were included. In the case of sleep disorders, our meta-analysis revealed that light therapy significantly improved sleep efficiency (MD = −2.42, 95% CI = −3.37 to −1.48, p < 0.00001), increased interdaily stability (MD = −0.04, 95% CI = −0.05 to −0.03, p < 0.00001), and reduced intradaily variability (MD = −0.07, 95% CI = −0.10 to −0.05, p < 0.00001). With respect to psychotic behavior, light therapy was found to alleviate depression (MD = −2.55, 95% CI = −2.98 to −2.12, p < 0.00001) as well as reduce agitation (MD = −3.97, 95% CI = −5.09 to −2.84, p < 0.00001) and caregiver burden (MD = −3.57, 95% CI = −5.28 to −1.87, p < 0.00001). Conclusion Light therapy leads to significant improvement in sleep and psychobehavioral symptoms and is associated with relatively fewer side effects in patients with AD, indicating its potential as a promising treatment option for AD.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer’s disease: A meta-analysis

Zang,

Liu,

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers

Abstract: The generic and reference formulations were bioequivalent, as the 90% CIs for C, AUC, and AUC were within the range of 80% to 125%.

Cited by 1 publication

References 13 publications

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer’s disease: A meta-analysis

The effect of light therapy on sleep disorders and psychobehavioral symptoms in patients with Alzheimer’s disease: A meta-analysis

Contact Info

Product

Resources

About